Nykode Therapeutics ASA banner

Company Overview

Business Description

Sector
Health Care
Industry
Biotechnology
Headquarters
Norway NO
Employees
135
IPO date
Jan 27, 2020

Nykode Therapeutics is a biotechnology company that develops DNA-based vaccines and immunotherapy candidates for cancer and infectious diseases. Its main work is to design vaccine programs that train the immune system to recognize specific targets, then move those candidates through research and clinical testing. The company is not a drug seller in the usual sense; it is building a pipeline of experimental medicines around its core vaccine technology.

The company’s customers are mainly large pharmaceutical partners, research collaborators, and eventually patients if its products win regulatory approval. Today it makes money mostly through collaboration and licensing deals, research funding from partners, and other biotech-style partnership payments tied to its technology and development programs. If its candidates succeed, future revenue would also come from product sales or royalties.

What makes Nykode different is that it sits earlier in the drug value chain than a traditional drugmaker. Instead of manufacturing a broad portfolio of approved medicines, it focuses on creating a platform that can be used to build multiple vaccine candidates from the same underlying technology. That gives it a business model centered on scientific development, partnerships, and long timelines to reach the market.

Nykode Therapeutics ASA Investor Relations

Address
Oslo Science Park, Gaustadalleen 21
Oslo
Norway

Business Segments

Therapeutic vaccines

Nykode develops DNA-based vaccines and other immune therapies for cancer and infectious diseases. The company designs the drug candidates, runs preclinical and clinical studies, and advances them toward approval.

Customers and revenue model

Vaccine platform licensing

Nykode also uses its vaccine delivery platform to support partner drug programs. It supplies the underlying technology and scientific know-how so other companies can build vaccines on it.

Customers and revenue model

Management

Mr. Michael Thyring Engsig

Chief Executive Officer

Biography unavailable

Mr. Harald Gurvin

Chief Financial Officer

Biography unavailable

Mr. Ulrich Blaschke

Chief Technology Officer

Biography unavailable

Dr. Agnete B. Fredriksen Ph.D.

Chief Scientific Officer & Business Development

Biography unavailable

Ms. Louise Stubbe

Chief Legal Officer

Biography unavailable

Dr. Klaus Edvardsen M.D., Ph.D.

Chief Research & Development Officer

Biography unavailable

1 / 6